Gene aberrations for precision medicine against lung adenocarcinoma

Lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, is often triggered by an aberration in a driver oncogene in tumor cells. Examples of such aberrations are EGFR mutation and ALK fusion. Lung adenocarcinoma harboring such mutations can be treated with anticancer drugs that target the aberrant gene products. Additional oncogene aberrations, including RET, ROS1, and NRG1 fusions, skipping of exon 14 of MET, and mutations in BRAF, HER2, NF1, and MEK1, were recently added to the list of such “druggable” driver oncogene aberrations, and their responses to targeted therapies are currently being evaluated in clinical trials. However, approximately 30% and 50% of LADCs in patients in Japan and Europe/USA, respectively, lack the driver oncogene aberrations listed above. Therefore, novel therapeutic strategies, such as those that exploit the vulnerabilities of cancer cells with non‐oncogene aberrations, are urgently required. This review summarizes the current status of research on precision medicine against LADC and enumerates the research priorities for the near future.

[1]  P. Stephens,et al.  Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Sugano,et al.  Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit. , 2016, Cancer research.

[3]  T. Kohno,et al.  Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  K. Yanagisawa,et al.  ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1 , 2016, Nature Communications.

[5]  Marcin Imielinski,et al.  Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers , 2015, Nature Genetics.

[6]  Manish B. Patel,et al.  Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Thomas P. Howard,et al.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.

[8]  M. Ladanyi,et al.  EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. , 2015, Cancer discovery.

[9]  Steven Piantadosi,et al.  Patient-centric trials for therapeutic development in precision oncology , 2015, Nature.

[10]  C. Lovly,et al.  Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade , 2015, Clinical Cancer Research.

[11]  Yoshitaka Seki,et al.  Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks , 2015, Biomolecules.

[12]  J. Shih,et al.  Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  K. Vousden,et al.  Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation. , 2015, Trends in cell biology.

[14]  Christopher I Amos,et al.  TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[15]  J. Yokota,et al.  Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. , 2015, Cancer research.

[16]  T. Kohno,et al.  Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan). , 2015 .

[17]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[18]  田原 康玄,et al.  生活習慣病とgenome-wide association study , 2015 .

[19]  A. Bossler,et al.  Germline mutations predisposing to non-small cell lung cancer , 2015, Familial Cancer.

[20]  Y. Shim,et al.  Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR , 2015, Oncotarget.

[21]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[22]  Shingo Matsumoto,et al.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.

[23]  J. Yokota,et al.  TSPAN12 is a critical factor for cancer–fibroblast cell contact-mediated cancer invasion , 2014, Proceedings of the National Academy of Sciences.

[24]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[25]  J. Ross,et al.  RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  K. Kumamoto,et al.  A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. , 2014, Carcinogenesis.

[27]  B. Reva,et al.  MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking , 2014, Clinical Cancer Research.

[28]  J. Yokota,et al.  NEK9-dependent proliferation of cancer cells lacking functional p53 , 2014, Scientific Reports.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[30]  Yang Zhang,et al.  P-155ALK, ROS1 AND RET FUSIONS IN 1139 LUNG ADENOCARCINOMAS: A COMPREHENSIVE STUDY OF COMMON AND FUSION PATTERN-SPECIFIC CLINICOPATHOLOGIC, HISTOLOGIC AND CYTOLOGIC FEATURES , 2014 .

[31]  B. Pasche,et al.  Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. , 2014, JAMA.

[32]  Lei Wang,et al.  ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. , 2014, Lung cancer.

[33]  Koji Tsuta,et al.  Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  J. Yokota,et al.  Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma , 2014, Clinical Cancer Research.

[35]  M. Meyerson,et al.  Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. , 2014, The Journal of clinical investigation.

[36]  David Piwnica-Worms,et al.  Contribution of p53 to metastasis. , 2014, Cancer discovery.

[37]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[38]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[39]  C. Roberts,et al.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.

[40]  T. Kohno,et al.  RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.

[41]  I. Petersen,et al.  CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[42]  Koichi Goto,et al.  RET fusion gene: Translation to personalized lung cancer therapy , 2013, Cancer science.

[43]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[44]  J. Yokota,et al.  A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. , 2013, Cancer research.

[45]  Olivier Michielin,et al.  Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Ladanyi,et al.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[47]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Aebi,et al.  A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[51]  S. Aebi,et al.  A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  Yusuke Nakamura,et al.  A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population , 2012, Nature Genetics.

[53]  Tomoya Yamaguchi,et al.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. , 2012, Cancer cell.

[54]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[55]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[56]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[57]  P. Broderick,et al.  Variation in TP63 is Associated with Lung Adenocarcinoma in the UK Population , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[58]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Hiroshi Sakamoto,et al.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.

[60]  A. Gemma,et al.  F1000 highlights , 2010 .

[61]  Ying Wang,et al.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. , 2009, American journal of human genetics.

[62]  Shingo Matsumoto,et al.  Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. , 2009, Cancer research.

[63]  Erika Avila-Tang,et al.  Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies , 2008, PLoS medicine.

[64]  Kenji Suzuki,et al.  Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[65]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[66]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[67]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[68]  J. Yokota,et al.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.

[69]  H. Koong,et al.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[71]  A. Berns,et al.  Oncogene addiction: sometimes a temporary slavery. , 2004, Cancer cell.

[72]  Liping Liu,et al.  Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung , 2016 .

[73]  B. Reva,et al.  MAP 2 K 1 ( MEK 1 ) Mutations De fi ne a Distinct Subset of Lung Adenocarcinoma Associated with Smoking , 2015 .

[74]  T. Kohno,et al.  Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  J. Pardinas,et al.  Re: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.